ANORECTAL APPLICATOR (AR-1)™
The Ancer Medical AR™ is a first of its kind, disposable brachytherapy applicator designed specifically for the treatment of anal and rectal cancers. The AR™ combines unique innovations with proven brachytherapy technology to bring a new Ancer to the question of anorectal cancer treatment.
ANCER MEDICAL, AR-1™ CLINICAL CASE STUDY
The patient, a 71 year old female was found to have a low lying rectal cancer initially treated with chemotherapy but was not a candidate for pelvic radiotherapy due to previous radiotherapy for cervical cancer in the 1970’s. As an alternative to an abdominoperineal resection, endoluminal high-dose brachytherapy was chosen.
Evaluation of a New MRI Compatible Brachytherapy Ano-rectal Applicator
Materials and Methods: The newly designed ano-rectal (AR) applicator (figure 1) is a multichannel, single use applicator with two concentric balloons. The inner balloon supports 8 radially symmetric source lumens; the outer balloon provides separation between the mucosal wall and the source lumens. The effective treatment zone of the applicator, in which the source lumens maintain the cylindrical geometry, is 10 cm long and is delineated by two central markers for positioning and treatment verification.
Prospective Evaluation of Endoluminal High Dose Rate Brachytherapy with Concurrent Chemotherapy for Rectal or Anal Cancer Patients: Initial Clinical Results
Purpose: To present initial clinical results of a prospective dose escalation protocol of endoluminal high dose rate (HDR) brachytherapy with concurrent chemotherapy for rectal or anal cancer patients undergoing non-operative management.
ESOPHAGEAL APPLICATOR (E-APP)™
The E-APP™ is a first of its kind, disposable brachytherapy applicator designed specifically for the treatment of upper GI cancers. Five independently operable balloons are designed to maintain the central position of the source catheter in both straight and curved anatomy allowing for closer proximity of the target to the source while maintaining distance for healthy tissue.
ANCER MEDICAL, E-App™ CLINICAL CASE STUDY
Purpose: In this study, we present the clinical implementation of a novel transoral balloon centering esophageal applicator (BCEA) and the initial clinical experience in high-dose-rate (HDR) brachytherapy treatment of esophageal cancer, using this applicator.
Clinical Use of a Novel Balloon Based Esophageal Brachytherapy Applicator
Purpose: High dose rate endoesophageal brachytheropy is an option in the management of primary and recurrent esophageal cancer in inoperable patients. In review of a series of patients treated at our institute (Folkert et al Brachytheropy 2013) we found HDR brachytheropy was safe and well tolerated, but was associated with a high rate of local recurrence. To overcome the limitation of surface dose and enable a dose escalation study we designed a novel balloon based applicator (Cohen and Goodman, Brachytheropy 2015). Here we report on the initial clinical use of this applicator.
Initial Experience in High-dose-rate Brachytherapy Treatment of the Esophagus Using a Novel Esophageal Applicator
Purpose: The purpose of the study is to report the initial experience in the treatment of locally advanced esophageal carcinoma with high-dose-rate (HDR) brachytherapy using a novel transoral balloon centering esophageal applicator (E-APP, Ancer Medical).tor.
The Edge ERB™ (Endorectal Balloon)
The Edge ERB™ is a unique saddle shaped balloon designed to cradle the prostate and provide superior, repeatable immobilization. The thoughtful collection of design features promotes enhanced ease of use and accuracy during both therapy and treatment planning, giving you and your patients the EDGE in treating their prostate cancer.
Pilot Study of the dose sparing capability and inter-fraction repeatability of a shape optimized endorectal balloon for proton beam prostate cancer treatment
Purpose: The treatment of prostate cancer with proton beam radiation requires Results: precise positioning of the patient to deliver prescription dose to the target structure while sufficiently sparing critical structures. We evaluate the dose sparing capability and inter-faction repeatability throughout a patient's treatment course using a new endorectal balloon (Edge ERB, Ancer Medical, Hialeah, FL,